Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-22T08:25:37.911Z Has data issue: false hasContentIssue false
  • English
  • Français

Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: Results from the STAR study

Published online by Cambridge University Press:  16 April 2020

David Taylor ,
Linda Hanssens ,
Jean-Yves Loze ,
Miranda Pans ,
Gilbert L'Italien  and
Ronald N. Marcus
David Taylor*
Affiliation:
South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, LondonSE5 8AZ, UK School of Biomedical Sciences, King's College, London
Linda Hanssens
Affiliation:
Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium
Jean-Yves Loze
Affiliation:
Otsuka Pharmaceutical France SAS, Paris, France
Miranda Pans
Affiliation:
Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium
Gilbert L'Italien
Affiliation:
Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA
Ronald N. Marcus
Affiliation:
Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492, USA
*
*Corresponding author. South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK. Tel.: +44 (0)20 3228 5040; fax: +44 (0)20 3228 5279. E-mail addresses: [email protected] (D. Taylor), [email protected] (L. Hanssens), [email protected] (J.-Y. Loze), [email protected] (M. Pans), [email protected] (G. L'Italien), [email protected] (R.N. Marcus).
Get access

Abstract

Objective

To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC).

Method

This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference.

Results

A total of 555 patients were randomised to receive aripiprazole (n = 284) or SOC (n = 271). The OC data at Week 26, reported that more respondents rated the study medication as ‘much better’ compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, P < 0.001) and caregivers (58% vs 30%, P = 0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC – mean change from baseline in QLS total score of 16.21 vs 10.01 (P < 0.001) at Week 26 (OC data set). A greater proportion of patients (93% vs 85%; P = 0.005) in the aripiprazole group had a satisfactory response on the EQ-5D Self Care Scale; all other EQ-5D scores were similar.

Conclusion

The study findings suggest that quality of life and patient medication preference measures were better for aripiprazole than for SOC.

Keywords

SchizophreniaAripiprazoleAtypical antipsychoticNaturalistic studyQuality of lifePatient preference
Type
Original article
Information
European Psychiatry , Volume 23 , Issue 5 , August 2008 , pp. 336 - 343
Copyright
Copyright © Elsevier Masson SAS 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Tel.: +32 2 352 7152; fax: +32 2 352 7887.

2

Tel.: +33 1 4708 0000; fax: +33 1 4751 8809.

3

Tel.: +32 2 352 7740; fax: +32 2 352 7800.

4

Tel.: +1 203 677 6572; fax: +1 203 677 5797.

5

Tel.: +1 203 677 6763; fax: +1 203 677 7695.

References

Awad, A.G.Voruganti, L.N.Impact of atypical antipsychotics on quality of life in patients with schizophrenia CNS Drugs 18 2004 877–893.Google Scholar
Corey-Lisle, PKHardy, SAImpellizzeri, CA. Aripiprazole vs haloperidol in acute mania: health-related quality of life (HRQoL). Abstract and poster presented at the 56th Institute on Psychiatric Services, Atlanta, GA, USA, October 6–10, 2004.Google Scholar
de Millas, W.Lambert, M.Naber, D.The impact of subjective well-being under neuroleptic treatment on compliance and remission Dialogues Clin Neurosci 8 2006 131–136.Google Scholar
Dolan, P.Modelling valuations for EQ-5D health states Medical Care 35 1997 1095–1108.Google Scholar
EuroQol Group EuroQol—a new facility for the measurement of health-related quality of life Health Policy 16 1990 199–208.Google Scholar
Gilmer, T.P.Dolder, C.R.Lacro, J.P.Folsom, D.P.Lindamer, L.Garcia, P. et al Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia Am J Psychiatry 161 2004 692–699.Google Scholar
Haro, J.M.Edgell, E.T.Novick, D.Alonso, J.Kennedy, L.Jones, P.B. et al Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study Acta Psychiatr Scand 111 2005 220–231.Google Scholar
Heinrichs, D.W.Hanlon, T.E.Carpenter, W.T. Jr.The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome Schizophr Bull 10 1984 388–398.Google Scholar
Jones, P.B.Barnes, T.R.Davies, L.Dunn, G.Lloyd, H.Hayhurst, K.P. et al Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 2006 1079–1087.Google Scholar
Karow, A.Naber, D.Subjective well-being and quality of life under atypical antipsychotic treatment Psychopharmacology (Berl) 162 2002 3–10.Google Scholar
Kerwin, R.Millet, B.Herman, E.Banki, C.M.Lublin, H.Pans, M. et al A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients: Schizophrenia Trial of Aripiprazole (STAR) study Eur Psychiatry 22 7 2007 433–443.Google Scholar
Konnopka, A.Gunther, O.H.Angermeyer, M.C.Konig, H.H.Discriminative ability, construct validity and sensitivity to change of the EQ-5D quality of life questionnaire in paranoid schizophrenia Psychiatr Prax 33 2006 330–336.Google Scholar
Lambert, M.Naber, D.Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life CNS Drugs 18 Suppl 2 2004 5–17.Google Scholar
Lieberman, J.A.Stroup, T.S.McEvoy, J.P.Swartz, M.S.Rosenheck, R.A.Perkins, D.O. et al Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209–1223.Google Scholar
Lindstrom, E.Bingefors, K.Patient compliance with drug therapy in schizophrenia: economic and clinical issues Pharmacoeconomics 18 2000 106–124.Google Scholar
L'Italien, GHanssens, LMarcus, RMcQuade, RCarson, WBeuzen, J-N. Metabolic effects of aripiprazole versus Standard of Care (The STAR Trial). American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May 20–25, 2006.Google Scholar
Mitchell, A.J.Adherence behaviour with psychotropic medication is a form of self-medication Med Hypotheses 68 1 2007 12–21.Google Scholar
Nasrallah, H.A.Lasser, R.Improving patient outcomes in schizophrenia: achieving remission J Psychopharmacol 20 6 Suppl 2006 57–61.Google Scholar
NICE Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia 2002 London: United Kingdom: National Institute for Clinical Excellence.Google Scholar
Prieto, L.Novick, D.Sacristan, J.A.Edgell, E.T.Alonso, J.A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study Acta Psychiatr Scand Suppl 107 416 2003 24–29.Google Scholar
Prieto, L.Sacristan, J.A.Hormaechea, J.A.Casado, A.Badia, X.Gómez, J.C.Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients Curr Med Res Opin 20 2004 827–835.Google Scholar
Roick, C.Thierfelder, K.Heider, D.Klemm, T.Paschke, R.Angermeyer, M.C.Quality of life instruments and health state preferences to assess effects of medical interventions for mentally and medically ill patients Psychiatr Prax 31 2004 128–137.Google Scholar
Sebastian, C.S.Glazer, W.Buckley, P.F.Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia Curr Med Chem 11 2004 329–342.Google Scholar
Swartz, M.S.Perkins, D.O.Stroup, T.S.Davis, S.M.Capuano, G.Rosenheck, R.A. et al Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study Am J Psychiatry 164 3 2007 428–436.Google Scholar
Tandon, R.Marcus, R.N.Stock, E.G.Riera, L.C.Kostic, D.Pans, M. et al A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA) Schizophr Res 84 2006 77–89.Google Scholar
Voruganti, L.Cortese, L.Owyeumi, L.Kotteda, V.Cernovsky, Z.Zirul, S. et al Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study Schizophr Res 57 2002 201–208.Google Scholar
Wolf, J.Janssen, F.Lublin, H.Salokangas, R.K.R.Allain, H.Smeraldi, E. et al A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA) Curr Med Res Opin 23 2007 2313–2323.Google Scholar
Submit a response

Comments

No Comments have been published for this article.